RecruitingPhase 2NCT06998628

Pentoxifylline as Anti-Inflammatory in Patients With Rheumatoid Arthritis

Clinical Study Evaluating the Effect of Pentoxifylline as Anti Inflammatory in Patients With Rheumatoid Arthritis


Sponsor

Tanta University

Enrollment

50 participants

Start Date

Jun 2, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

Rheumatoid arthritis (RA) is a long-term inflammatory condition that leads to gradual damage of joints lined by synovial membranes, along with various potential effects outside of the joints. While RA can affect any joint, it typically involves the metacarpophalangeal, proximal interphalangeal, and metatarsophalangeal joints, as well as the wrists and knees. Symptoms related to the joints and surrounding tissues include swelling, tenderness upon touch, morning stiffness, and significant difficulty moving the affected joints


Eligibility

Min Age: 18 YearsMax Age: 70 Years

Inclusion Criteria4

  • Patients with active rheumatoid arthritis (not in remission) according to American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) \[9\] i.e., 28 joints disease activity score (DAS 28) \>2.6.
  • Patients receiving the conventional DMARDs.
  • Both sexes.
  • Age range between 18and 70 years old

Exclusion Criteria5

  • Patients with retinal or cerebral hemorrhage.
  • Patients with renal and hepatic dysfunction.
  • Patients with hypersensitivity to study medications.
  • Pregnant and lactating females.
  • Patients receiving biological or synthetic DMARDs

Interventions

DRUGMethotrexate

Methotrexate (MTX) is a chemotherapy agent and immune-system suppressant. It is used to treat cancer, autoimmune diseases, and ectopic pregnancies. Types of cancers it is used for including breast cancer, leukemia, lung cancer, lymphoma, gestational trophoblastic disease, and osteosarcoma. Methotrexate is also used to treat rheumatoid arthritis and other inflammatory conditions.

DRUGPentoxifylline

Pentoxifylline (also known as oxpentifylline) is a methylxanthine derivative with strong hemorrheologic effects. In the United States, it is primarily used to treat intermittent claudication. Studies in both humans and animals have demonstrated that pentoxifylline therapy induces various physiological changes at the cellular level


Locations(1)

Faculty of Medicine, Al-Azhar University

Damietta, Damietta Governorate, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06998628


Related Trials